<img height="1" width="1" style="display:none;" alt="" src="https://px.ads.linkedin.com/collect/?pid=2653956&amp;fmt=gif">
Image Overlay - First-In-Human Trial Begins for Novel NHL/MM Immunotherapy
Image Overlay - First-In-Human Trial Begins for Novel NHL/MM Immunotherapy

First-In-Human Trial Begins for Novel NHL/MM Immunotherapy

First-In-Human Trial Begins for Novel NHL/MM Immunotherapy

A clinical trial is now underway for a first-in-class immunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma (NHL) or multiple myeloma (MM). The treatment, NKTR-255, which harnesses patients' own natural killer cells to combat these rare but devastating diseases, was developed by Nektar therapeutics, and the trial is being conducted at Cancer Treatment Centers of America (CTCA) in Phoenix, Arizona. Yourway has the resources and expertise to support all clinical trials, whether they are investigating a conventional small molecule drug or next-generation immunotherapies like NKTR-255.

Back to Index
Media

Upcoming Events

Precision in Pharma Supply Chain & Logistics Summit (Munich)

April 15-16, 2024
Science Congress Center Munich

GCSG 2024 US Conference

April 21-24, 2024
Naples, Florida

Media

Articles

The At-home Trial Experience: Leveraging value-chain to reach and retain patients

Open chat
Come chat with us!
Hello! How can I help you?